Showing 8891-8900 of 10817 results for "".
- iRestore Expands Reseller Programhttps://practicaldermatology.com/news/irestore-expands-reseller-program/2457677/The iRestore Laser Hair Growth System from Freedom Laser Therapy is now more widely available, thanks to an expanded reseller program for the drug-free, pain-free laser hair restoration device. The reseller program now offers an affiliate model that enables sales representative
- BioPharmX: FDA Grants CARC Waiver; Post-Hoc Analysis for BPX-01 Completehttps://practicaldermatology.com/news/biopharmx-fda-grants-carc-waiver-post-hoc-analysis-for-bpx-01-complete/2457686/The FDA has waived its requirement for a dermal carcinogenicity study for BPX-01 from BioPharmX Corporation, eliminating several years of non-clinical research normally required for FDA review. BPX-01, a novel topical gel formulation of minocycline for the treatment of inflammatory
- New From Candela: Vbeam Primahttps://practicaldermatology.com/news/new-from-candela-vbeam-prima/2457694/Recently FDA-cleared, the Vbeam Prima from Candela offers two wavelengths to effectively treat a broad range of skin condi
- LEO Pharma and Advancing Innovation in Dermatology Partner to Help Finance Accelerator Fundhttps://practicaldermatology.com/news/leo-pharma-and-advancing-innovation-in-dermatology-partner-to-help-finance-accelerator-fund/2457713/LEO Pharma and its Boston-based R&D innovation unit LEO Science & Tech Hub, and Advancing Innovation in Dermatology (AID) will each contribute $500,000 into the recently created Advancing Innovation in Dermatology Accelerator Fund. This non-profit fund is unique in its approach for suppor
- New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatologyhttps://practicaldermatology.com/news/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology/2457721/BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology&mda
- Michael Mazen Jafar is New Chief Marketing Officer at Evolushttps://practicaldermatology.com/news/michael-mazen-jafar-is-new-chief-marketing-officer-at-elovus/2457722/Evolus, Inc. has expanded its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juve
- New Data from DermTech Presented at International Investigational Dermatology Meetinghttps://practicaldermatology.com/news/new-data-from-dermtech-presented-at-international-investigational-dermatology-meeting/2457724/DermTech, Inc., has announced the publication of two clinical study abstracts at the 2018 International Investigational Dermatology meeting
- PellePharm Presents New Data in BCChttps://practicaldermatology.com/news/pellepharm-presents-new-data-in-bcc/2457731/PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, presented new data from its clinical and scientific research programs at the International Investigative Dermatology (IID) Meeting in Orlando, FL. The data, presented i
- New CFO at Evolus, Inc.https://practicaldermatology.com/news/new-cfo-at-evolus-inc/2457744/Lauren Silvernail is the new Chief Financial Officer and Executive Vice President, Corporate Development at Evolus, Inc. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance The
- Glenmark Pharmaceuticals Presents New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at IID Meetinghttps://practicaldermatology.com/news/glenmark-pharmaceuticals-presents-new-data-on-gbr-830-an-investigational-anti-ox40-monoclonal-antibody-at-iid-meeting/2457760/Glenmark Pharmaceuticals shared data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID)